Prevalence of obstructive sleep apnoea syndrome following oropharyngeal cancer treatment: A prospective cohort study.
OBJECTIVE
To evaluate the prevalence of obstructive sleep apnoea syndrome (OSAS) in a population of patients treated for an advanced oropharyngeal cancer (AJCC Stage III or IV), depending on treatment strategy, and to evaluate its impact on quality of life.


METHODS
Prospective cohort study.


METHODS
University Teaching Hospital of La Conception, Marseille, France.


METHODS
Fifty-one disease-free patients were included. Forty-one patients received a combined chemoradiotherapy, while 10 patients were treated by surgery followed by chemoradiotherapy.


METHODS
Every patient underwent a formal sleep consultation and was asked to complete the Epworth Sleepiness Scale and EORTC QLQ C-30 and the EORTC H&N 35 questionnaires. A home overnight respiratory polygraphy was performed in every subject.


RESULTS
The mean time between the end of cancer treatment and the OSAS analysis was 54.04 months [20; 84]. An OSAS was found in 25.49% of our patients. There was no significant difference between patients treated with either surgery (30%) or CRT (24.39%), P=.79. The EORTC QLQ C-30 questionnaire showed a significant difference between positive and negative OSAS groups in the Global Health Status Scale (50.64 vs 67.11, P=.02) and in the fatigue item (35.04 vs 17.25, P=.03).


CONCLUSIONS
Our population with advanced oropharyngeal cancer, whatever the treatment strategy it may be, was at risk of developing OSAS with negative impact on quality of life. A routine screening and treatment of OSAS seems necessary to improve the quality of life of patients treated for advanced oropharyngeal cancer.
Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, APHM, Aix Marseille Univ, Marseille, France.
A
A
Loth
Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, APHM, Aix Marseille Univ, Marseille, France.
J
J
Michel
IRD, UMR_S 912 (SESSTIM), Aix-Marseille Université, Marseille, France.|INSERM, UMR_S 912 (SESSTIM), Marseille, France.|Service Biostatistiques et Technologies de l'Information et de la Communication, Hôpital Timone, APHM, Marseille, France.
R
R
Giorgi
Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, APHM, Aix Marseille Univ, Marseille, France.
L
L
Santini
Centre du sommeil et Service de Neurophysiologie Clinique, Hôpital Timone, APHM, Marseille, France.
M
M
Rey
Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, APHM, Aix Marseille Univ, Marseille, France.
J-M
JM
Elbaum
Service Biostatistiques et Technologies de l'Information et de la Communication, Hôpital Timone, APHM, Marseille, France.
N
N
Roux
Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, APHM, Aix Marseille Univ, Marseille, France.|Laboratoire Parole et Langage (LPL), CNRS UMR, Aix-Marseille Université, Aix-en-Provence, France.
A
A
Giovanni
Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, APHM, Aix Marseille Univ, Marseille, France.
P
P
Dessi
Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, APHM, Aix Marseille Univ, Marseille, France.|Laboratoire Parole et Langage (LPL), CNRS UMR, Aix-Marseille Université, Aix-en-Provence, France.
N
http://orcid.org/0000-0001-7070-0780
N
Fakhry
D000328:Adult; D000368:Aged; D059248:Chemoradiotherapy; D015331:Cohort Studies; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D010611:Pharyngectomy; D017286:Polysomnography; D015995:Prevalence; D011788:Quality of Life; D020181:Sleep Apnea, Obstructive / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D011795:Surveys and Questionnaires; D013997:Time Factors
head and neck cancer; obstructive sleep apnoea; oropharynx; sleep disorders